Figure 5.

Inhibition of miR-135b Inhibits OS Metastasis and CSC-Induced Tumorigenesis and Recurrence

(A) Inhibition of miR-135b suppressed CD133^high Saos-2 cell-induced tumor formation in nude mice. CD133^high Saos-2 cells transfected with antisense nucleotides of miR-13b (ASO miR-135b) or negative control nucleotides (Ctrl. Oligo). After 12 hr of transfection, cells were subcutaneously injected into nude mice (n = 5). (B) Combination treatment of CDDP and antagomiR-135b inhibited OS recurrence. CD133^high Saos-2 cells were subcutaneously injected into nude mice (n = 6 mice/group). When the mean tumor volume reached 70 ± 21 mm³, the mice were intraperitoneally injected with CDDP and antagomiR-135b (miR-135b in) or with the antagomiR negative control every 3 days for six total rounds. The tumor volume was measured every 3 days. (C) The proportion of CD133-positive cells derived from xenograft tumors is shown. Tumors were collected from xenograft mice (n = 3/group) 12 days after the start of treatment. (D) Inhibition of miR-135b significantly suppressed the ability of LM5 cells to metastasize to the lungs in vivo (n = 6/group). **p < 0.01.